Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-hydroxyflavanone (2HF) is a citrus-derived flavonoid that acts as a potent inhibitor of RLIP (RALBP1), an ATP-dependent efflux pump involved in the transport of glutathione-electrophile conjugates and the endocytosis of the epidermal growth factor receptor (EGFR). By inhibiting RLIP, 2HF downregulates the expression of key homologous recombination (HR) DNA repair genes, including BRCA1, BRCA2, and PALB2. This mechanism creates a transcriptomic environment similar to HR-deficient (HRD) mutated cells, effectively inducing a "BRCAness" phenotype. Consequently, 2HF has demonstrated the ability to sensitize BRCA-wildtype cancer cells, such as certain ER+ and triple-negative breast cancers, to the cytotoxic effects of PARP inhibitors. Preclinical studies suggest its utility in reducing spontaneous carcinogenesis and overcoming chemotherapy resistance in various malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-hydroxyflavanone.